In addition, mutations in phosphatase and tensin homolog (PTEN) and KEAP1 have been nominated as potential drivers of de novo resistance to immune checkpoint inhibition in NSCLC [188,190]. This evidence concerns the gene PTEN and non-small cell lung carcinoma.